ICU Medical (ICUI) – Investment Analysts’ Recent Ratings Changes

A number of research firms have changed their ratings and price targets for ICU Medical (NASDAQ: ICUI):

• 2/20/2026 – ICU Medical had its price target raised by Piper Sandler from $172.00 to $178.00. They now have an “overweight” rating on the stock.
• 2/20/2026 – ICU Medical had its price target raised by KeyCorp from $175.00 to $180.00. They now have an “overweight” rating on the stock.
• 2/15/2026 – ICU Medical was upgraded by Wall Street Zen from “hold” to “buy”.
• 2/7/2026 – ICU Medical was downgraded by Wall Street Zen from “buy” to “hold”.
• 1/22/2026 – ICU Medical had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 1/19/2026 – ICU Medical was upgraded by Wall Street Zen from “hold” to “buy”.
• 1/11/2026 – ICU Medical was downgraded by Wall Street Zen from “buy” to “hold”.
• 1/3/2026 – ICU Medical was upgraded by Wall Street Zen from “hold” to “buy”.

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.